Real-world dataset demonstrates favorable safety profile of liposomal amphotericin B for the treatment of invasive aspergillosis in high-risk haemato-oncology patients

Maertens, J.;Herbrecht, R.;Fodil, S.;De Voeght, A.;Azoulay, E.;et.al.
(2025) 35th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) — Location: (Austria) Vienna (11.April.2025)

Files

2025_Maertens_ESCMID_P2937.pdf
  • Open Access
  • Adobe PDF
  • 160.12 KB
Download

Details

Authors
  • Maertens, J.
    Author
  • Herbrecht, R.
    Author
  • Fodil, S.
    Author
  • De Voeght, A.
    Author
  • De Greef, Julienorcid-logoUCLouvain
    Author
  • Azoulay, E.
    Author
Show more
Abstract
BACKGROUND : Liposomal amphotericin B (Ambisome®) (LAmB) remains a cornerstone treatment for invasive fungal disease, due to its broad spectrum of activity, proven efficacy and lack of resistance. Evidence shows a significantly reduced risk of adverse events (AEs) over conventional AmB and other lipid formulations. LAmB is an alternative to voriconazole (VOR) for first-line treatment of invasive aspergillosis (IA), in cases of hepatotoxicity, dermatologic or visual AEs or QTc prolongation. This largest available real world evidence (RWE) study evaluates the AE profiles of LAmB and VOR in the high-risk haemato-oncology setting. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Maertens, J., Herbrecht, R., Fodil, S., De Voeght, A., Delavigne, K., Liebregts, T., Rodriguez Veiga, R., De Greef, J., Uzunov, M., Vazquez, L., Penack, O., Albasanz-Puig, A., Ngirabacu, M. C., Mehra, V., Teschner, D., Albert, L., Pfeifer, C., Brennan-Benson, P., Vanstraelen, K., & Azoulay, E. (2025). Real-world dataset demonstrates favorable safety profile of liposomal amphotericin B for the treatment of invasive aspergillosis in high-risk haemato-oncology patients. CMI Communications, 2025(1), 105086. https://hdl.handle.net/2078.5/274758 (Original work published 2025)